1015 Capital Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,196
Closed -$28.8K – 440
2026
Q2
$28.8K Buy
1,196
+1
+0.1% +$26 0.02% 165
2026
Q1
$33.6K Hold
1,195
– – 0.03% 162
2025
Q4
$29.8K Hold
1,195
– – 0.03% 166

Other funds holding PFE

1015 Capital Partners's PFE Position: Q3 2026 in Review

1015 Capital Partners sold out of Pfizer (PFE) in Q3 2026, closing a stake of 1,196 shares — an estimated $28.8K sold.

1015 Capital Partners first reported a position in PFE in Q4 2025 and held it in 3 quarters. The position peaked at $33.6K in Q1 2026. 2,918 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • 1015 Capital Partners reported no remaining Pfizer position as of Q3 2026 after selling out during the quarter.
  • 1015 Capital Partners sold 1,196 Pfizer shares in Q3 2026, an estimated $28.8K.
  • 1015 Capital Partners first reported a position in Pfizer in Q4 2025 and held it in 3 quarters.
  • 1015 Capital Partners's Pfizer position peaked at $33.6K in Q1 2026.
  • 2,918 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on 1015 Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.